Once a biosimilar cliff happens, how many companies in India would be able to play that is going to be of interest. At this point in time, it does not seem to be a very broad-based bouquet of companies which we can bet on.
For More Details Visit-
via Like generics 10 yrs ago, expect a biosimilar cliff by 2020-2022: Vinay Khattar, Edelweiss Financial Services
No comments:
Post a Comment